Saltar al contenido
Merck

Magnesium sulfate during anticipated preterm birth for infant neuroprotection.

Nursing for women's health (2013-02-13)
Lisa Merrill
RESUMEN

Advances in medical care of preterm infants, including the widespread use of surfactant and antenatal steroids, and improvements in ventilation management, have increased the survival rates of some of the most vulnerable infants. Yet, the risk of neurologic impairment and long-term medical complications remains a concern. Recently, the use of magnesium sulfate during anticipated preterm birth has been identified as a potential treatment to reduce adverse neurologic outcomes among preterm infants. This article discusses the use of magnesium sulfate for anticipated preterm birth to reduce neurologic impairment in preterm infants, including current clinical practice guidelines and implications for nurses.

MATERIALES
Número de producto
Marca
Descripción del producto

Sigma-Aldrich
Sulfato de magnesio, anhydrous, ReagentPlus®, ≥99.5%
Sigma-Aldrich
Sulfato de magnesio heptahidratado, ACS reagent, ≥98%
Sigma-Aldrich
Sulfato de magnesio heptahidratado, ReagentPlus®, ≥99.0%
Sigma-Aldrich
Sulfato de magnesio, puriss. p.a., drying agent, anhydrous, ≥98.0% (KT), powder (very fine)
Sigma-Aldrich
Sulfato de magnesio heptahidratado, BioReagent, Molecular Biology, suitable for plant cell culture, ≥99.0%
Sigma-Aldrich
Sulfato de magnesio, BioReagent, suitable for cell culture, suitable for insect cell culture
Sigma-Aldrich
Magnesium sulfate solution, Molecular Biology, 1.00 M±0.04 M
Sigma-Aldrich
Sulfato de magnesio heptahidratado, BioUltra, ≥99.5% (KT)
Sigma-Aldrich
Magnesium sulfate solution, BioUltra, Molecular Biology
Sigma-Aldrich
Sulfato de magnesio, ≥99.99% trace metals basis
Sigma-Aldrich
Sulfato de magnesio heptahidratado, BioXtra, ≥99.0%